任天堂
医学
吡非尼酮
特发性肺纤维化
肺癌
重新调整用途
多西紫杉醇
癌症
肺纤维化
疾病
肿瘤科
内科学
肺
生态学
生物
作者
Hartmut Jaeschke,Sara S. Fois,Alessandro G. Fois,Antonio Cossu,Giuseppe Palmieri,Gianfranco Pintus
标识
DOI:10.2174/0929867327999200730173748
摘要
Idiopathic pulmonary fibrosis (IPF) is an aggressive pulmonary disease which shares several molecular, pathophysiological and clinical aspects with lung cancer, including high mortality rates. The antifibrotic drugs Nintedanib and Pirfenidone have recently been introduced in clinical practice for the treatment of IPF. Nintedanib is also used for the treatment of several malignancies, including non-small cell lung cancer (NSCLC) in combination with Docetaxel, while Pirfenidone showed some anti-neoplastic effects in preclinical studies. On the other hand, novel targeted agents and immunotherapies have been introduced in the last decade for the treatment of NSCLC, and some of them showed anti-fibrotic properties in recent studies. These evidences, based on the common pathophysiological backgrounds of IPF and lung cancer, make possible the mutual or combined use of anti-fibrotic and anti-neoplastic drugs to treat these highly lethal diseases. The aim of the present review is to depict the current scientific landscape regarding the repurposing of anti-neoplastic drugs in IPF and anti-fibrotic drugs in lung cancer, and to identify future research perspectives on the topic.
科研通智能强力驱动
Strongly Powered by AbleSci AI